Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Radiolabeled Compounds in the Development of Cytotoxic Agents

Author(s): Kalevi J.A. Kairemo and Marja Tahtinen

Volume 10, Issue 24, 2004

Page: [2923 - 2934] Pages: 12

DOI: 10.2174/1381612043383458

Price: $65

Abstract

With the help of radiolabeled compounds, drug development can be made faster; especially with microdosing and radiopharmacokinetics, some elements of phase I and II trials necessary for conventional cancer drug development can be avoided. Imaging may proof the principle of actual targeting. However, radiopharmacokinetics is dependent on the radionuclide, the radionuclide linker with the drug and the size of the drug molecule. Optimally, some of the drug molecule atoms may be replaced with a radionuclide that can be visualized. In this article drug development utilizing radionuclides both in PET and SPET has been reviewed.

Keywords: cancer chemotherapies, radionuclide imaging, pharmacokinetics, pharmacodynamics, single photon emission tomography, positron emission tomography, cytotoxic compounds, targeting


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy